Seroatlas · Human Serome Atlas

PRKAG2

5'-AMP-activated protein kinase subunit gamma-2

Also known as: AAKG, AAKG2, AAKG2_HUMAN, CMH6, H91620p, WPWS

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9UGJ0
Gene
PRKAG2
Ensembl
ENSG00000106617
Chromosome
7
Canonical length
569 aa
Protein class
Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm

OverviewNCBI Gene

AMP-activated protein kinase (AMPK) is a heterotrimeric protein composed of a catalytic alpha subunit, a noncatalytic beta subunit, and a noncatalytic regulatory gamma subunit. Various forms of each of these subunits exist, encoded by different genes. AMPK is an important energy-sensing enzyme that monitors cellular energy status and functions by inactivating key enzymes involved in regulating de novo biosynthesis of fatty acid and cholesterol. This gene is a member of the AMPK gamma subunit family. Mutations in this gene have been associated with Wolff-Parkinson-White syndrome, familial hypertrophic cardiomyopathy, and glycogen storage disease of the heart. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jan 2015]

Canonical amino-acid sequenceUniProt

569 residues, UniProt reviewed canonical sequence.

>Q9UGJ0|PRKAG2
     1  MGSAVMDTKK KKDVSSPGGS GGKKNASQKR RSLRVHIPDL SSFAMPLLDG DLEGSGKHSS
    61  RKVDSPFGPG SPSKGFFSRG PQPRPSSPMS APVRPKTSPG SPKTVFPFSY QESPPRSPRR
   121  MSFSGIFRSS SKESSPNSNP ATSPGGIRFF SRSRKTSGLS SSPSTPTQVT KQHTFPLESY
   181  KHEPERLENR IYASSSPPDT GQRFCPSSFQ SPTRPPLASP THYAPSKAAA LAAALGPAEA
   241  GMLEKLEFED EAVEDSESGV YMRFMRSHKC YDIVPTSSKL VVFDTTLQVK KAFFALVANG
   301  VRAAPLWESK KQSFVGMLTI TDFINILHRY YKSPMVQIYE LEEHKIETWR ELYLQETFKP
   361  LVNISPDASL FDAVYSLIKN KIHRLPVIDP ISGNALYILT HKRILKFLQL FMSDMPKPAF
   421  MKQNLDELGI GTYHNIAFIH PDTPIIKALN IFVERRISAL PVVDESGKVV DIYSKFDVIN
   481  LAAEKTYNNL DITVTQALQH RSQYFEGVVK CNKLEILETI VDRIVRAEVH RLVVVNEADS
   541  IVGIISLSDI LQALILTPAG AKQKETETE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRKAG2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.47
Highest tissue expression
122 nTPM

Expression across tissuesHPA

Tissue

  • heart muscle: 122 nTPM
  • basal ganglia: 46 nTPM
  • blood vessel: 39 nTPM
  • urinary bladder: 38 nTPM
  • liver: 32 nTPM
  • small intestine: 25 nTPM

Single-cell type

  • renal connecting tubule cells: 763 nCPM
  • renal collecting duct principal cells: 742 nCPM
  • prostatic glandular cells: 521 nCPM
  • monocytes: 517 nCPM
  • endometrial glandular cells: 480 nCPM
  • endometrial luminal cells: 432 nCPM

Immune cell

  • basophil: 26 nTPM
  • neutrophil: 11 nTPM
  • eosinophil: 11 nTPM
  • memory B-cell: 9.6 nTPM
  • classical monocyte: 9.4 nTPM
  • naive CD8 T-cell: 7.3 nTPM

Brain region

  • hippocampal formation: 35 nTPM
  • cerebral cortex: 32 nTPM
  • amygdala: 30 nTPM
  • hypothalamus: 30 nTPM
  • basal ganglia: 27 nTPM
  • pons: 27 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PRKAG2.

Disease | AllUniProt

Conditions PRKAG2 is implicated in, by any mechanism.

Disease | GeneticClinVar

27 pathogenic / likely-pathogenic of 1,490 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.26
gnomAD pLI
1
gnomAD missense Z
1.65
DepMap mean gene effect
0.04
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PRKAG2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRKAG2 as an antibody target. Whether an autoantibody or antibody against PRKAG2 could matter depends on whether native PRKAG2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRKAG2 is annotated as secreted, so native PRKAG2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label PRKAG2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PRKAG2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...